The IRA Impact: Unlocking New Commercial Realities in Pharma

Topics of Discussion

The Inflation Reduction Act (IRA) is poised to reshape the pharmaceutical industry, and commercial leaders need to be prepared for the sweeping changes it will bring. Join Dan Snyder from Performance Development Group (PDG) and healthcare policy expert Chuck Collins for an in-depth discussion on the IRA’s key provisions and how it will impact your organization.

In this on-demand webinar, you’ll gain insights into:

• The potential challenges pharmaceutical companies will face under this new legislation
• Actionable steps commercial leaders should consider immediately
• How the IRA will affect brand and pricing strategies and the broader US healthcare market
• Opportunities for forward-thinking pharmaceutical companies

Don’t miss out on this critical conversation that will help prepare your teams for the future.

Speakers

Dan Snyder

Sr. VP of Sales, Performance Development Group

Dan Snyder is a seasoned sales and business leader with a rich background in the pharmaceutical/biotech industry. Currently serving as the Senior VP of Sales for Performance Development Group (PDG), Dan has held leadership roles at Astra USA, Diachii Sankyo, Shire, Nitromed, Clarus Therapeutics, Syneos Health, and Delta Point. Adept at overcoming challenges, Dan is known for his passion for sales, commitment to coaching excellence, building high performing teams, and ability to achieve outstanding results.